News

CTCE-0214 is designed to trigger trafficking of immune system cells and stem cells, as well as regeneration of white blood cells and platelets. The company hopes that the

Decreased insulin activity is known to contribute to type 2 diabetes and other complications such as obesity, and these targets have demonstrated the ability to regulate insulin activity

The new company, to be called Cyclacel Pharmaceuticals, will have two clinical stage, mechanism-targeted, small molecule drug candidates in cancer, a third candidate expected to enter clinical trials

The deal provides Amgen with full ownership of panitumumab, a potential blockbuster anticancer compound that the companies have been developing together. Shareholders of Abgenix will receive $22.50 in

As a result of NKS104’s disappointing performance, Novartis intends to book a $266 million charge in the fourth quarter of 2005 to fully write off the remaining value

The company anticipates completing its pivotal phase III trial for Pennsaid by the end of 2005. Preliminary results from the trial are likely to be disclosed in January

Set for UK release in January 2006, Sirco is the first heart health product to contain the patented ‘Fruitflow’ technology. Provexis said Fruitflow has been developed to help

Understanding the nature of cancer stem cells could result in new therapies that specifically target those cells which are thought to be the driving force of tumor progression.

CollaGenex will make an initial payment of $750,000 for 51% of the shares of SansRosa. The remaining shares will be purchased upon the achievement of various milestones. If